In 2025, China's surgical robot industry continued to develop across multiple types simultaneously. In various technical pathways such as laparoscopy, orthopedics, neurosurgery, natural orifice, vascular intervention, and dental, both domestic and imported systems advanced concurrently. The number of products, clinical applications, and installation scale all showed phased growth.

Based on public bidding information, corporate disclosures, and industry data, MedRobot has researched and analyzed the sales structure and system type landscape of surgical robots in China for 2025, focusing on presenting the developmental status of different technical categories.

Statistical Scope and Data Sources

This statistical report includes the sales volume from January 1 to December 31, 2025, for all categories of surgical robots in the Chinese market and for Chinese brands in overseas markets.

Specifically, it includes:

• Purchases by public hospitals (including public winning bids and some non-public procurement channels).

• Purchases by private hospitals.

• Technical services (including business models such as fee-for-service and leasing-like arrangements).

• Overseas sales of Chinese brands.

• System shipments corresponding to OEM/joint brands.

The following are not included in the statistics:

• Pure navigation systems or non-robotic system products.

• Systems with unclear product attributes or registration information.

The statistical foundation primarily comes from:

• Public winning bid data for public hospitals already published by MedRobot.

  • 2025 Panoramic Observation and Landscape Analysis of Laparoscopic Surgical Robot Winning Bids – Based on Public Winning Bid Data from Public Hospitals

  • 2025 Panoramic Observation and Landscape Analysis of Orthopedic Surgical Robot Winning Bids – Based on Public Winning Bid Data from Public Hospitals

• Annual sales and delivery information supplemented by some manufacturers beyond public winning bid data.

It should be noted that there may be objective differences in statistical caliber and information completeness among different manufacturers. Simultaneously, due to compliance requirements, some international companies can only provide public winning bid data for reference. For listed companies, the relevant data in this report is for industry research and structural observation only; complete and accurate annual data should be based on the companies' official disclosures.

Overall Sales Volume: Still Primarily Supported by Laparoscopic and Orthopedic Systems

Under the above research scope, MedRobot estimates:

• The total annual sales volume of surgical robots in China for 2025 was no less than 611 units (2024: 313 units).

• This covers major segments including laparoscopy, orthopedics, neurosurgery, dental, natural orifice, puncture, and vascular intervention, encompassing sales in the Chinese market and overseas sales of Chinese brands. This figure can be considered a conservative statistical result based on currently available information.

The current sales structure of surgical robots in China exhibits distinct characteristics by type:

• Laparoscopic surgical robots remain the category with the largest installation base and procedure volume.

• Orthopedic surgical robots continue to see increasing volume in spinal, joint, and trauma fields.

• Neurosurgical robots and dental robots experienced significant growth.

• Natural orifice and interventional robots are still in the early stages of clinical expansion and commercialization.

Overall, the industry's sales growth in 2025 came more from the continued penetration of mature types rather than the rapid volume expansion of new types.

Sales Landscape by Type

Laparoscopic Surgical Robots: Largest Sales Scale, Most Concentrated Competition

In 2025, sales in this segment were no less than 229 units (2024: 157 units).

Laparoscopic surgical robots remain the most mature type in the Chinese market. The system structure is predominantly master-slave operation with multiple robotic arms, clinically covering urology, general surgery, thoracic surgery, gynecology, and other fields.

From a sales structure perspective:

• Imported systems still hold a significant share of the existing base.

• After products from multiple domestic companies entered clinical use, a multi-brand parallel landscape gradually formed.

• Among new installations, the proportion of domestic systems continues to rise, becoming a significant source of sales growth.

• The market characteristics of laparoscopic robots have shifted from a "single-brand dominance" phase to a "multi-system coexistence" phase.

Sales Data Statistics for Laparoscopic Robots in 2025

Orthopedic Surgical Robots: Growth Driven by Specific Surgical Procedures

Sales of orthopedic surgical robots in 2025 were no less than 168 units (2024: 94 units), making it one of the most mature segments. In recent years, with the increase in the number of domestic manufacturers, improved product maturity, and continuous diversification of business models, the overall usage barrier for orthopedic surgical robots has been consistently lowering:

• Equipment price systems are gradually decreasing.

• Models like technical services and leasing reduce upfront investment pressure.

• Training systems and clinical support are gradually improving.

• Willingness to participate among grassroots hospitals has significantly increased.

Sales Data Statistics for Orthopedic Robots in 2025

Neurosurgical Robots: High Market Concentration

In 2025, sales of neurosurgical robots were no less than 121 units (2024: 20 units), with extremely high market concentration.

The unit price of such equipment is relatively low, but clinical scenarios are highly specialized, and hospitals' installation pace is relatively rational.

Sales Data Statistics for Neurosurgical Robots in 2025

Dental, Natural Orifice, Puncture, and Vascular Interventional Robots: Still in Early Stages, Significant Room for Sales Growth

Sales of dental robots showed noticeable growth; natural orifice, puncture, and vascular interventional robots are still in the clinical validation and commercial exploration stages. Their contribution to the overall market size remains limited, but they are widely regarded as potential growth directions for the future.

• Dental Robots: Annual sales no less than 64 units (2024: 29 units).

Sales Data Statistics for Dental Robots in 2025

• Natural Orifice Robots: Annual sales no less than 13 units (2024: 4 units).

Sales Data Statistics for Natural Orifice Robots in 2025

• Puncture Robots: Annual sales no less than 9 units (2024: 1 unit).

Sales Data Statistics for Puncture Robots in 2025

• Vascular Interventional Robots: Annual sales no less than 7 units (2024: 8 units).

Sales Data Statistics for Vascular Interventional Robots in 2025

The Essence of Sales Growth Lies in Clinical Demand and Market Diversification 

Overall, the Chinese surgical robot market in 2025 exhibited:

• Leading manufacturers expanding into overseas markets.

• Increased acceptance by private hospitals.

• Steady growth in clinical demand.

  
  

The growth in sales stems from:

• Improved system maturity.

• Gradual clarification of clinical pathways.

• Increased hospital acceptance of robotic surgery models.

This indicates that China's surgical robot industry is transitioning from a "concept-driven stage" to a "structured development stage."

Future changes in the market landscape will depend more on system stability, clinical adaptation capability, and long-term commercial operation capability.

MedChina, February 6, 2026